



"Our journey with cancer began October 2, 2012 when I was diagnosed with breast cancer. Our whole family shouldered my diagnosis and all of us worked together through treatment, including chemotherapy, surgery, radiation, some unwanted side effects, and reconstructive surgeries. It took a while to come out on the other side of the cancer diagnosis.

That's why the support of the staff we encountered along the way was vital to our journey. We are especially grateful for the services provided after cancer... counseling, support groups, and activities to encourage good health.

We are able to take advantage of many of these programs because we chose to receive my care in Flint, just 15 minutes from home. Thank you for being there for us!"

- Molly Ann Cox



Molly's husband Bill was a constant source of support during her cancer journey. As a caregiver, he drove to nearly all appointments, comforted her, and eased the burden of the treatment process.



As a medical oncologist, I understand the importance of care being accessible and convenient. It can be the most important factor. Having to travel can prohibit a patient from seeking the treatment and support services they need. With the strong clinical, research and complementary therapy programs Karmanos Cancer Institute at McLaren Flint (KCI at McLaren Flint) has in place, patients and their physicians can feel confident that they will receive safe, high-quality care that is close to home.

We continue to strengthen our core treatment services, develop opportunities to participate in research, and expand programs that provide additional support to our patients and promote prevention and early detection within our community. This year, KCI at McLaren Flint received ACR accreditation in Radiation Oncology and welcomed two distinguished surgical oncologists that will continue to strengthen the breadth and depth of surgical oncology care that is available in the Flint region. In addition, as a result of national studies validating that lung cancer screenings saves lives in certain patients, this year McLaren Flint has also implemented a lung cancer screening program. Michigan is fortunate to have many excellent cancer treatment centers. Now, with Karmanos Cancer Institute being a part of McLaren Health Care, we have expanded the scope of Karmanos to 11 of our community-based programs. For a patient facing cancer, having the best care means being treated with compassion by a skilled team, using the most effective treatments. We believe complementary therapy services such as counseling, art therapy, nutritional therapy, and wellness classes are also a significant benefit in the physical and emotional healing process. Like Molly and her family, choosing to receive treatment in Flint allows local patients and their caregivers the time and convenience to take advantage of the full spectrum of care available in this community.

Jut & Me

Justin Klamerus, MD, MMM Executive Vice President of Community-Based Cancer Programs Assistant Professor of Oncology Karmanos Cancer Institute

Clinical Oncology Research Medical Director McLaren Health Care



On the cover. Molly Ann Cox, surrounded by her daughters Allison Milligan (left) and Katrina Oliver (right).

# Foundational Quality Goals:

National Accreditations



American College of Surgeons Commission on Cancer



American College of Radiology Radiation Oncology Practice



Quality Oncology Practice Initiative -American Society of Clinical Oncology

# State Quality Programs

- Michigan Radiation Oncology Quality Consortium (MROQC) participant
- Michigan Oncology Quality Consortium (MOQC) participant



In addition, Karmanos at McLaren Flint has also obtained prestigious certification from

the National Accreditation Program for Breast Centers.



# SURGICAL

This year, Karmanos Cancer Institute at McLaren Flint welcomed two fellowship trained surgical oncologists with exceptional clinical education and experience. Smit Singla, MD, MRCSEd, MSc, and Tolutope Oyasiji, MD, MRCSI, are at the forefront of cancer treatment using innovative techniques, technologies, and clinical advances to provide the highest standards of cancer care for our patients.

Minimally invasive techniques such as laparoscopic and robotic surgery are used to remove tumors while saving as much normal tissue and function as possible.

**Regional therapy** can sometimes help extend and improve quality of life for some patients with advanced cancers, when traditional chemotherapy or surgery ceases to be a good option.

The offices of Dr. Singla and Dr. Oyasiji are located within the Karmanos Cancer Institute at McLaren Flint and surgeries are performed at McLaren Flint or McLaren Surgery Center. These physicians join a staff of 22 physicians providing surgical options for cancer patients.



"We emphasize a compassionate, empathetic and comprehensive approach in the management of cancer. We follow scientific, evidence-based practice using a minimally invasive approach. Ultimately, our patients are the center and focus of all cancer treatment given."

- Dr. Oyasiji and Dr. Singla





# CONTINUUM OF CARE

## Surgical Oncology Services:

- Minimally invasive techniques: endoscopic, laparoscopic and robotic-assisted
- 16 well-equipped operating suites
- Dedicated post-surgical care unit

#### Procedures:

- Adrenalectomy
- Esophagectomy
- Entrectomy
- Gastrectomy
- GE junction tumors
- Pancreatectomy
- Hepatectomy
- Colectomy
- Proctectomy
- Thyroidectomy
- ParathyroidectomySpecialized regional therapy:
- HIPEC Hyperthermic
   Intraperitoneal
   Chemotherapy for cancer of the lining of the abdominal cavity
- ILI/ILP Isolated Limb Infusion/Isolated Limb Perfusion for in-transit melanoma
- Radiofrequency ablation and microwave ablation
- Transarterial
  Chemoembolization (TACE)

## Radiation Oncology Services:

- External beam radiotherapy services
- Image-guided Radiation Therapy (IGRT)
- Intensity Modulated
   Radiation Therapy (IMRT)
- On board CT scanning
- Brachytherapy (internal radiation therapy services)
  - Low dose rate (LDR)
     permanent seed implantation
  - High dose rate (HDR)
     computer-guided treatment
     and placement of fiducial
     marker seeds
- Clinical trials

## Medical Oncology Services:

- Targeted therapy
- Clinical trials
- Genetic counseling
- Biologic therapy
- Chemotherapy
- Hormonal therapy

#### Multidisciplinary Conferences

- Weekly tumor conferences:
- Breast
- Thoracic
- General oncology cases
- Monthly conferences:
- Neuro oncology cases

# SCHELLES COMMUNITY The McLaren Comprehensive Lung Cancer

**Health Screenings** 

(2014 Fiscal year)

- Approximately 10,000 screened for signs of breast cancer
- 180 screened for signs of **lung cancer**
- 66 received FIT tests to screen for colorectal cancer

The McLaren Comprehensive **Lung Cancer Detection Program** is embracing recent industry changes and technological advances to improve outcomes for lung cancer patients. McLaren Flint has created a streamlined program specifically for those at a higher risk for developing lung cancer, incorporating screening, diagnosis, treatment and support services. The goal is early detection to treat cancer while it is at a less advanced stage.

#### **American Cancer Society**

By working with, and supporting the American Cancer Society, our patients benefit.

- 16 women attended a Look Good Feel Better beauty and emotional healing program
- Approximately 1,060 patient rides were provided to and from treatment through the Road to Recovery transportation assistance program

#### **Support Services**

- Social work
- Nutrition
- Physical, occupational and speech therapy
- Financial counseling
- Stop Smoking workshops

#### **Support Groups**

- Women's cancer
- Multiple myeloma
- Prostate cancer

# Cancer Survivor Celebration

Special guests Nick Karmanos (lower left) and prostate cancer survivor Reg Tidball (with wife and daughter below) shared how their lives were changed because of cancer. Physicians and staff visited with more than 400 patients and caregivers in attendance.



# RESEARCH

The newly formed McLaren Center for Research and Innovation is focused on having the right infrastructure and dedicated professional in place at McLaren sites to find better ways to deliver care. Karmanos Cancer Institute at McLaren Flint is engaging in more clinical trials and research programs to expand promising treatment options for our patients and help advance the future of cancer treatment outcomes.

KCI at McLaren Flint is a participant in the following quality and research programs:

- Michigan Radiation Oncology Quality Consortium (MROQC) is a collaborative group of specialists across the state of Michigan working together on quality improvement projects to impact the radiation treatment experience for patients with breast or lung cancer. MROQC's goal is to identify best practices in radiation therapy that minimize the side effects that patients may experience from radiation treatment.
- Michigan Breast Oncology
  Quality Initiative (MiBOQI)
  collects accurate data on women
  diagnosed with breast cancer in
  Michigan. Our data coordinator
  collects demographic, diagnostic,
  treatment, and outcome data,
  and reports this information to
  MiPOQI for evaluation of current
  standards of care and to form
  quality improvement efforts that will
  advance breast cancer treatments in
  order to improve patient outcomes.



As part of the Karmanos Cancer Institute's mission to expand its clinical trials program, Kiran Devisetty, MD, was recently appointed the Community Radiation Oncology Medical Director to spearhead this directive. Dr. Devisetty has been working closely with the teams at Flint, Lapeer, Mount Clemens, Mt. Pleasant, Owosso, and Petoskey to coordinate a systematic effort to optimize infrastructure, improve technologic capabilities, and enhance staff education with the goal of creating a standard foundation from which the same clinical trials can be



Kiran Devisetty, MD

open throughout the system.
Ultimately, these efforts will create a robust community clinical research program that mirrors the excellence of Karmanos' research

mission in order to improve patient access to cutting edge research and opportunities.

As data coordinator for the MROQC research initiative, Amy Nolin (right) meets with eligible patients and provides education on the participation requirements and schedule.

2 O Annual Report Lisa Ash, RHIA, CPHQ QUALITY MANAGEMENT

Frederick R. Armenti, MD THORACIC SURGERY

Madan L. Arora, MD

Jean Battles, LMSW, ASCW

CASE MANAGEMENT/ SOCIAL WORK
PSYCHOSOCIAL SERVICES
COORDINATOR

Courtenay Hamilton, RN
DIRECTOR OF PATIENT CARE SERVICES
MCLAREN FLINT

McKenzie Bigger, RT (T)
QUALITY IMPROVEMENT
COORDINATOR

Kristin Chevrette, RN, OCN
PATIENT NAVIGATOR/ ONCOLOGY
NURSE

Kiran Devisetty, MD

Nancy Dunn, RN
CLINICAL RESEARCH COORDINATOR

David S. Eilender, MD

MEDICAL ONCOLOGY

Hesham E. Gayar, MD RADIATION ONCOLOGY

Sandeep Grewal, MD

MEDICAL ONCOLOGY

Justin F. Klamerus, MD

EVP/COMMUNITY-BASED PROGRAMS
KARMANOS CANCER INSTITUTE

Emily Kuberski, RD REGISTERED DIETITIAN

Lauren Lawrence
DIRECTOR OF COMMUNITY-BASED
PROGRAMS
KARMANOS CANCER INSTITUTE

Linda L. Lawrence, MD

Harish Madala, MD
RESIDENT PHYSICIAN

Shams Mistry, MD
RESIDENT PHYSICIAN

Jack L. Nettleton, MD

Mindi Odom

AMERICAN CANCER SOCIETY

Tolutope Oyasiji, MD, MRCSI SURGICAL ONCOLOGY Sukamal Saha, MD, FACP, FRCS(C)
SURGICAL ONCOLOGY, CLP

Marti Seaman, RN, BSN HOSPICE BRANCH MANAGER

T. Trevor Singh, MD, FACP MEDICAL ONCOLOGY, CHAIRMAN CANCER COMMITTEE

Smit Singla, MD, MRCSEd, MSc

SURGICAL ONCOLOGY

Peter Skiles REGIONAL DIRECTOR, CANCER SERVICES SOUTH CENTRAL REGION

Colleen Streeter, RHIT, CTR CANCER CONFERENCE COORDINATOR

Tamar Swain, RN

Vincent Waller, RN
NURSE MANAGER

Lori Walters, PT
DIRECTOR, REHABILITATION SERVICES

Brent Wheeler
VP, ANCILLARY SUPPORT SERVICES

David A. Wiese, MD, PhD PATHOLOGY

Ben Wolbert, RN
MANAGER PATIENT CARE SERVICES
COMMUNITY OUTREACH
COORDINATOR

Kimberly Wright, CTR
ONCOLOGY DATA COORDINATOR
CANCER REGISTRY QUALITY
COORDINATOR







#### 2014 Data Summary

Total Number of Cases Reviewed	
Total Number of Completed Cases	
Total Number of Analytic Cases (diagnosed and/or treated at McLaren-Flint)	
Total Number of Cases Reportable to State of Michigan Cancer Registry105	
Total Number of Cases Reviewed Which Were Non-Reportable197	




#### Summary by Body System, Sex, Class, Status and Best CS/AJCC Stage Report

Primary Site	Total (%)	M S	ex F	Class of Anly	of Care NA	Sta Alive	tus Exp	Stg 0	Stg I	Stage Dist Stg II	tribution – Stg III	Analytic ( Stg IV	Cases O		Blank/Inv
ORAL CAVITY & PHARYNX	25 (2.3%)	16		25		21		0			10				
Tongue	9 (0.8%)	6			0			0		0	4	4	0	0	0
Salivary Glands	5 (0.5%)	0	5	5	0	5	0	0	0				0	0	0
Floor of Mouth	2 (0.2%)	2	0	2	0			0		0	0		0	0	0
Gum & Other Mouth	2 (0.2%)	2	0	2	0	2	0	0		0	0		0	0	0
Tonsil	3 (0.3%)	3	0		0		0	0	0	0		2	0	0	0
Hypopharynx	4 (0.4%)	3		4	0	4	0	0	0		2	0	0		0
DIGESTIVE SYSTEM	156 (14.0%)	84	72	156		98	58	6	29	35	37	40			
Esophagus	22 (2.0%)	18	4	22	0	13		0	5			5	0	2	0
Stomach	9 (0.8%)	6			0	5	4	0		2		2	0		0
Small Intestine	7 (0.6%)	4			0		0	1	2	0			0	0	0
Colon Excluding Rectum	48 (4.3%)	21	27	48	0	35	13	5		12	15	8	0		0
Cecum	14	4	10	14	0			1			8		0	0	0
Appendix		0			0		0	0		0	0	0	0	0	0
Ascending Colon	8	4	4	8	0			1		2			0	0	0
Hepati c Flexure		1	0		0	0		0	0		0	0	0	0	0
Transverse Colon		3	8		0	8		1		5			0	0	0
Descending Colon		2			0		0	1	0			0	0	0	0
Sigmoid Colon		4	3		0	4	3	0		2	2	2	0	0	0
Large Intestine, NOS	3	3	0	3	0		2	1	0	0	0		0		0
Rectum & Rectosigmoid	25 (2.3%)	14		25	0	23	2	0	8	8			0		0
Rectosigmoid Junction	6	5		6	0	5		0	0	2	3		0	0	0
Rectum	19	9	10	19	0	18		0	8	6	4	0	0		0
Anus, Anal Canal & Anorectum	3 (0.3%)	1	2	3	0	3	0	0	0		2	0	0	0	0
Liver & Intrahepatic Bile Duct	7 (0.6%)	5	2		0	3	4	0		0		2	3	0	0
Liver	6	4	2	6	0	2	4	0		0		2	2	0	0
Intrahepatic Bile Duct		1	0		0		0	0	0	0	0	0		0	0
Gallbladder	2 (0.2%)	1		2	0			0	0	0			0	0	0
Pancreas	32 (2.9%)	13	19	32	0	8	24	0	3	9	0	19	0		0
Peritoneum, Omentum &	1 (0.1%)	1	0		0	0		0	0	0	0		0	0	0
RESPIRATORY SYSTEM	229 (20.6%)	123	106	229	0	142	87	4	71	19	66	64	1	4	0
Nose, Nasal Cavity & Middle E	ar 2 (0.2%)	1		2	0	2	0	0	0	0	0	2	0	0	0
Larynx	15 (1.4%)	11	4	15	0	15	0	2	4	2	5	2	0	0	0
Lung & Bronchus	211 (19.0%)	110	101	211	0	124	87	2	67	- 17	61	60	0	4	0
Trachea, Mediastinum & Other	1 (0.1%)	1	0		0	1 1	0	0	0	0	0	0		0	0
BONES & JOINTS	1 (0.1%)	0	1	1	0	1	0	0	0	0	0	0		0	0
Bones & Joints	1 (0.1%)	0		1	0	1	0	0	0	0	0	0		0	0
SOFT TISSUE	5 (0.5%)	2		5	0	5	0	0	1	3	1	0		0	0
Soft Tissue (including Heart)	5 (0.5%)	2	3	5	0	5	0	0				0	0	0	0
SKIN EXCLUDING BASAL &	15 (1.4%)	11	4	15	0	14	1	4		5		1	0	0	0
Melanoma Skin	15 (1.4%)	11	4	15	0	14		4	3	5	2		0	0	0
BREAST	237 (21.3%)	3	234	237	0	229		39	120	53	16		0	1	0
Breast		3						39		53	16	8			
breast	237 (21.3%)	3	234	237	0	229	8	39	120	53	10	δ	0		0

#### Summary by Body System, Sex, Class, Status and Best CS/AJCC Stage Report


Primary Site	Total (%)	M S	ex F	Class of Anly	of Care NA	Sta Alive	tus Exp	Stg 0	Stg I	Stage Dist Stg II	ribution - Stg III	- Analytic ( Stg IV	Cases O 88		Blank/Inv
FEMALE GENITAL SYSTEM	63 (5.7%)	0	63	63		53	10	1	40						
Cervix Uteri	3 (0.3%)	0		3	0	3	0	1		0		0	0	0	0
Corpus & Uterus, NOS	44 (4.0%)	0	44	44	0	38		0	33		5	4	0		0
Corpus Uteri	40	0	40	40	0	36	4	0	31		5	2	0		0
Uterus, NOS	4	0	4	4	0	2	2	0	2	0	0	2	0	0	0
Ovary	13 (1.2%)	0	13	13	0		4	0	4			5	0	0	0
Vagina	2 (0.2%)	0	2	2	0	2	0	0		0	0	0		0	0
Vulva	1 (0.1%)	0		1	0		0	0		0	0	0	0	0	0
MALE GENITAL SYSTEM	110 (9.9%)	110		110		108		0	10						
Prostate	105 (9.5%)	105	0	105	0	103	2	0		88	4		0	0	0
Testis	4 (0.4%)	4	0	4	0	4	0	0		0	0	0	0		0
Other Male Genital Organs	1 (0.1%)	1	0	1	0		0	0	0	0	0	0		0	0
URINARY SYSTEM	114 (10.3%)	75		114		100		26	42	23					
Urinary Bladder	59 (5.3%)	46	13	59	0	51	8	26		13	5	2			0
Kidney & Renal Pelvis	47 (4.2%)	23	24	47	0	42	5	0	31	5	4		0	0	0
Ureter	6 (0.5%)	4	2	6	0	5		0	0	4	2	0	0	0	0
Other Urinary Organs	2 (0.2%)	2	0	2	0	2	0	0	0		0	0		0	0
BRAIN & OTHER NERVOUS	19 (1.7%)	10		19		12		0							
Brain	9 (0.8%)	6		9	0	4	5	0	0	0	0	0		0	0
Cranial Nerves Other Nervous	10 (0.9%)	4		10	0	8	2	0	0	0	0	0	10	0	0
ENDOCRINE SYSTEM	30 (2.7%)	9		30		27		0	17						
Thyroid	27 (2.4%)	8	19	27	0	24		0	17		5	4	0	0	0
Other Endocrine including	3 (0.3%)	1	2	3	0		0	0	0	0	0	0		0	0
LYMPHOMA	39 (3.5%)	20		39		34		0							
Hodgkin Lymphoma	4 (0.4%)	2	2	4	0	4	0	0	0	4	0	0	0	0	0
Non-Hodgkin Lymphoma	35 (3.2%)	18	17	35	0	30	5	0	13	4			0		0
NHL - Nodal	17	8		17	0	14		0	4	2		4	0		0
NHL - Extranodal	18	10	8	18	0	16	2	0		2	0	5	0	2	0
MYELOMA	7 (0.6%)	3		7		5		0							
Myeloma	7 (0.6%)	3	4	7	0	5	2	0	0	0	0	0		0	0
LEUKEMIA	23 (2.1%)	11	12	23		14		0					23		
Lymphocytic Leukemia	9 (0.8%)	4	5	9	0		2	0	0	0	0	0		0	0
Myeloid & Monocytic Leukemia	13 (1.2%)	7		13	0			0	0	0	0	0	13	0	0
Acute Myeloid Leukemia	8	3	5	8	0			0	0	0	0	0	8	0	0
Chronic Myeloid Leukemia	5	4		5	0		0	0	0	0	0	0		0	0
Other Leukemia	1 (0.1%)	0		1	0		0	0	0	0	0	0		0	0
MESOTHELIOMA	4 (0.4%)	4		4		2		0							
Mesothelioma	4 (0.4%)	4	0	4	0	2	2	0		0		0	0	0	0
MISCELLANEOUS	34 (3.1%)	16		34		12	22	0							
Miscellaneous	34 (3.1%)	16	18	34	0	12	22	0	0	0	0	0	34	0	0





#### 2014 Distribution of Top Five Malignancies

1,111 Analytic Cases




#### 2014 Distribution by Age at Diagnosis

1,111 Analytic Cases



#### 2014 Distribution by County at Diagnosis


1,111 Analytic Cases



#### 2014 Distribution by AJCC Stage


1,111 Analytic Cases






#### 2014 Distribution of Four Major Sites by Age at Diagnosis

1,111 Analytic Cases




#### 2014 Distribution of Four Major Sites by AJCC Stage

1,111 Analytic Cases



#### 2014 Initial Treatment for Colorectal Cancer

105 Analytic Cases




#### 2014 Initial Treatment for Lung Cancer

212 Analytic Cases




 $^{2}$ 



#### 2014 Initial Treatment for Breast Cancer

238 Analytic Cases



#### 2014 Initial Treatment for Prostate Cancer

105 Analytic Cases

# RESOURCES

#### Women's Cancer Support Group

Karmanos Cancer Institute at McLaren Flint, Garden Level Conference Room The Women's Cancer Support Group is open to any woman with cancer. The monthly meetings focus on Self-Care.

Second Wednesday each month | 3:00 - 4:30 pm

#### US TOO Prostate Cancer Support Group

First Tuesday of each month | 7:00 pm Hospitality House, 3170 Beecher Road, Flint For further information visit ustoo.org or call (810) 877-0199.

#### Stop Smoking Workshop

First & Third Wednesday of each month | 3:00 - 4:30 pm Karmanos Cancer Institute at McLaren Flint, 4100 Beecher Road, Flint RSVP to (810) 342-5370.

#### Look Good...Feel Better!

Third Thursday of each month | 12:30 - 2:30 pm Karmanos Cancer Institute at McLaren Flint, 4100 Beecher Road, Flint Free makeup and skincare sessions for women who are undergoing treatment. To sign up, call American Cancer Society at (800) 227-2345.

#### Multiple Myeloma Support Group

Third Thursday of each month | 6:30 - 8:00 p.m.

McLaren Hospitality House, Conference Center,

3170 Beecher Road, Flint

For more information, please contact Starr & Carl Fittante at

(810) 820-1592 or Flintsgl@IMFSupport.org

Website: flint.support.myeloma.org

#### New Tomorrows Grief Support Group

Free ongoing grief education and support for anyone who has experienced the loss of a loved one. For information call (810) 496-8625.

#### Support Services Team

#### Jean Battles, LMSW, ACSW

Medical Social Worker (810) 342-3847

- Individual counseling
- Community referrals
- Help acquiring resources
- Consultation and coordination
- Problem solving
- Financial resource information

#### Kristin Chevrette, RN, OCN, BSN

Oncology Nurse Navigator (810) 342-3850

- Clarify medical concerns, questions and information
- Referral to community resources
- Liaison between physician offices
- Coordination of medical appointments

#### Emily Kuberski, RD

Registered Dietitian (810) 342-3823

- Provides nutritional counseling and information specific to each cancer patient
- Supplemental nutritional assistance

#### Gail Singer, MA, LPC, ATR

Art Therapist & Licensed Professional Counselor (810) 342-4206

- Individual counseling and/or art therapy in office or during chemotherapy
- Group sessions at the Flint Institute of Arts, during the women's cancer support group, and at monthly art workshops at Karmanos Cancer Institute at McLaren Flint
- Continuing support after treatment ends

#### Karla Byce, BHSA, HIT

Patient Accounts Coordinator (810) 342-3803

Help with questions regarding:

- Financial help options regarding medical costs
- Referrals to Medicaid advocates

25




The **Hospitality House at McLaren** is a unique service providing a convenient, comfortable and low-cost housing option for people who are traveling long distances to receive care at McLaren Flint. The beautiful facility is just steps away from the Cancer Institute and features 32 guest rooms. Additional amenities include:

- Large Gathering Room designed for relaxing and socializing
- Spacious Multi-Family Kitchen with four preparation areas and amble seating options

- Elegant Patio for outdoor dining and enjoyment
- Reading Room/Library
- A non-denominational Reflection Room
- Billiard Room
- Exercise Room
- Laundry Room
- Children's Playroom
- Multi-Use Room for specialized therapies such as art

- Conference space for educational programs and entertainment
- Gazebo overlooking natural area
- Herb and vegetable garden

Visit mclaren.org/HospitalityHouse for more details. For reservation information, please call (810) 820-9800.









McLAREN FLINT

401 South Ballenger Highway Flint, Michigan 48532-3638

NONPROFIT ORG. U.S. POSTAGE PAID FLINT, MI PERMIT NO. 70

For more information visit mclaren.org/flintcancer